Merck to Acquire Investigational B-Cell Depletion Therapy, CN201, from Curon Biopharmaceutical
Go back to Merck to Acquire Investigational B-Cell Depletion Therapy, CN201, from Curon Biopharmaceutical| Merck & Co. (NYSE: MRK) | Delayed: 147.98 -0.1 (0.07%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $148.08 | 52 Week High | $65.46 | |||
| Open | $148.16 | 52 Week Low | $47.97 | |||
| Day High | $151.46 | P/E | 100.67 | |||
| Day Low | $147.90 | EPS | $1.47 | |||
| Volume | 10,328,757 | |||||
